These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32024842)

  • 1. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing.
    Yu L; Kim J; Jiang L; Feng B; Ying Y; Ji KY; Tang Q; Chen W; Mai T; Dou W; Zhou J; Xiang LY; He YF; Yang D; Li Q; Fu X; Xu Y
    Nat Commun; 2020 Feb; 11(1):708. PubMed ID: 32024842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing.
    Zhu S; Chen W; Wang J; Qi L; Pan H; Feng Z; Tian D
    Theranostics; 2021; 11(7):3359-3375. PubMed ID: 33537092
    [No Abstract]   [Full Text] [Related]  

  • 3. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
    Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma.
    Zhang LF; Lou JT; Lu MH; Gao C; Zhao S; Li B; Liang S; Li Y; Li D; Liu MF
    EMBO J; 2015 Nov; 34(21):2671-85. PubMed ID: 26346275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
    PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
    Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
    Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
    Jung Y; Jang YJ; Kang MH; Park YS; Oh SJ; Lee DC; Xie Z; Yoo HS; Park KC; Yeom YI
    Mol Cells; 2013 Apr; 35(4):335-41. PubMed ID: 23515579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC8-dependent deacetylation of PKM2 directs nuclear localization and glycolysis to promote proliferation in hepatocellular carcinoma.
    Zhang R; Shen M; Wu C; Chen Y; Lu J; Li J; Zhao L; Meng H; Zhou X; Huang G; Zhao X; Liu J
    Cell Death Dis; 2020 Dec; 11(12):1036. PubMed ID: 33279948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: from gene expression to drug discovery.
    Lv WW; Liu D; Liu XC; Feng TN; Li L; Qian BY; Li WX
    BMC Cancer; 2018 Nov; 18(1):1150. PubMed ID: 30463528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
    Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma.
    Yang H; Zhu R; Zhao X; Liu L; Zhou Z; Zhao L; Liang B; Ma W; Zhao J; Liu J; Huang G
    Oncogene; 2019 Jun; 38(25):4915-4931. PubMed ID: 30858544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
    Taniguchi K; Sugito N; Kumazaki M; Shinohara H; Yamada N; Nakagawa Y; Ito Y; Otsuki Y; Uno B; Uchiyama K; Akao Y
    Cancer Lett; 2015 Jul; 363(1):17-27. PubMed ID: 25818238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
    Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression.
    Shang R; Pu M; Li Y; Wang D
    Oncol Rep; 2017 Apr; 37(4):2261-2269. PubMed ID: 28260073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antioxidant uncoupling protein 2 stimulates hnRNPA2/B1, GLUT1 and PKM2 expression and sensitizes pancreas cancer cells to glycolysis inhibition.
    Brandi J; Cecconi D; Cordani M; Torrens-Mas M; Pacchiana R; Dalla Pozza E; Butera G; Manfredi M; Marengo E; Oliver J; Roca P; Dando I; Donadelli M
    Free Radic Biol Med; 2016 Dec; 101():305-316. PubMed ID: 27989750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
    Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.
    Dayton TL; Gocheva V; Miller KM; Israelsen WJ; Bhutkar A; Clish CB; Davidson SM; Luengo A; Bronson RT; Jacks T; Vander Heiden MG
    Genes Dev; 2016 May; 30(9):1020-33. PubMed ID: 27125672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2.
    Chen YY; Zhang Q; Gui MH; Feng L; Cao PB; Zhou GQ
    Yi Chuan; 2024 Jan; 46(1):46-62. PubMed ID: 38230456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.